RxSight, Inc.
RXST · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.98 | 0.69 | -0.15 | 0.01 |
| FCF Yield | -1.68% | -3.34% | -17.47% | -15.15% |
| EV / EBITDA | -56.05 | -33.69 | -6.64 | -8.01 |
| Quality | ||||
| ROIC | -12.53% | -30.66% | -46.27% | -28.58% |
| Gross Margin | 70.71% | 60.36% | 43.52% | 19.99% |
| Cash Conversion Ratio | 0.62 | 0.86 | 0.88 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 41.87% | 57.98% | 49.46% | 116.03% |
| Free Cash Flow Growth | 51.76% | 24.22% | -31.29% | -23.60% |
| Safety | ||||
| Net Debt / EBITDA | 0.19 | 0.16 | -0.57 | -0.50 |
| Interest Coverage | -1,755.14 | -15.14 | -12.80 | -14.34 |
| Efficiency | ||||
| Inventory Turnover | 1.86 | 2.03 | 1.87 | 2.25 |
| Cash Conversion Cycle | 233.93 | 223.24 | 243.02 | 206.63 |